Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACTIQ vs EXENATIDE SYNTHETIC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Exenatide synthetic is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics the incretin hormone GLP-1, enhancing glucose-dependent insulin secretion from pancreatic beta cells, suppressing glucagon secretion, slowing gastric emptying, and promoting satiety.
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus,Reduction of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease (off-label use based on EXSCEL trial)
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
Subcutaneously 5 mcg twice daily within 60 minutes before morning and evening meals; may increase to 10 mcg twice daily after 1 month.
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Terminal elimination half-life is 2.4 hours for subcutaneous administration, supporting twice-daily dosing.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Exenatide is primarily degraded by proteolytic degradation (neutral endopeptidase) and renal filtration, with minimal hepatic metabolism.
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
Primarily renal via glomerular filtration and proteolytic degradation; approximately 30% of the dose is excreted unchanged in urine, with the remainder as metabolites in urine and feces.
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
Approximately 25% bound to plasma proteins, primarily albumin.
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
Volume of distribution is 0.2 L/kg, indicating limited extravascular distribution.
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
Subcutaneous: absolute bioavailability is approximately 65%.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
Cr Cl 30-50 m L/min: no adjustment; Cr Cl <30 m L/min: not recommended; ESRD on dialysis: contraindicated.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
No specific adjustment for mild to moderate hepatic impairment; not studied in severe impairment (Child-Pugh C).
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
Not approved for use in pediatric patients; safety and efficacy not established.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
No specific dose adjustment; use caution due to increased risk of renal impairment and hypoglycemia; monitor renal function.
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
No black box warning.
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Risk of acute pancreatitis; discontinue if suspected,Risk of hypoglycemia when used with insulin secretagogues or insulin,Renal impairment: increased risk of gastrointestinal adverse effects and acute renal failure; avoid in end-stage renal disease,Severe gastrointestinal disease: may exacerbate gastroparesis,Thyroid C-cell tumors: observed in rodent studies; monitor for serum calcitonin or thyroid masses,Immunogenicity: may develop anti-exenatide antibodies leading to loss of efficacy or injection site reactions
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
History of hypersensitivity to exenatide or any product components,Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2),End-stage renal disease (e GFR <15 m L/min/1.73 m²) or severe renal impairment (e GFR 15-29 m L/min/1.73 m²) if on dialysis,Severe gastrointestinal disease (e.g., gastroparesis)
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
Exenatide slows gastric emptying, which may reduce the rate and extent of absorption of oral medications. Take exenatide at least 1 hour before meals; for oral medications requiring rapid absorption (e.g., antibiotics, oral contraceptives), take them 1 hour before or 4 hours after exenatide. No specific food restrictions, but high-fat meals may increase nausea.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
Pregnancy Category C. In animal studies, exenatide caused reduced fetal growth, decreased ossification, and increased incidence of skeletal abnormalities at doses 5-13 times human exposure. No adequate human studies. Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
It is unknown whether exenatide is excreted in human breast milk. Due to potential for adverse reactions in nursing infants, caution should be exercised. M/P ratio not available. Consider developmental and health benefits of breastfeeding along with mother's clinical need for exenatide.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
No specific pharmacokinetic studies in pregnancy. Pregnancy-related weight gain, volume expansion, and renal changes may alter exenatide pharmacokinetics. Clinical trials did not establish a dose adjustment protocol; use the lowest effective dose titrated based on glycemic control. Discontinue prior to expected delivery (e.g., 48 hours) due to risk of delayed gastric emptying during labor.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
Exenatide is a GLP-1 receptor agonist used for T2DM. It slows gastric emptying, so administer at least 60 min before first meal of day. Avoid in severe renal impairment (Cr Cl <30 m L/min). Risk of acute pancreatitis; discontinue if suspected. Not for use in T1DM or DKA. Monitor for thyroid C-cell tumors (contraindicated if personal/family history of MTC or MEN 2).
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
Inject subcutaneously in abdomen, thigh, or upper arm, within 60 minutes before morning and evening meals (or before the two main meals of the day, at least 6 hours apart).,Do not administer after a meal; skip dose if a meal is skipped.,Store unused pens in refrigerator (36°F to 46°F). In-use pen can be kept at room temperature up to 86°F for up to 30 days.,Common side effects include nausea, vomiting, diarrhea, and headache; these often decrease over time.,Seek medical attention for severe abdominal pain (possible pancreatitis), rash or hives, difficulty breathing, or swelling of face/ lips (angioedema).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACTIQ vs EXENATIDE SYNTHETIC, answered by our medical review team.
ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. EXENATIDE SYNTHETIC is a GLP-1 Receptor Agonist that works by Exenatide synthetic is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics the incretin hormone GLP-1, enhancing glucose-dependent insulin secretion from pancreatic beta cells, suppressing glucagon secretion, slowing gastric emptying, and promoting satiety.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACTIQ and EXENATIDE SYNTHETIC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. The standard adult dose of EXENATIDE SYNTHETIC is: Subcutaneously 5 mcg twice daily within 60 minutes before morning and evening meals; may increase to 10 mcg twice daily after 1 month.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACTIQ and EXENATIDE SYNTHETIC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. EXENATIDE SYNTHETIC is classified as Category A/B. Pregnancy Category C. In animal studies, exenatide caused reduced fetal growth, decreased ossification, and increased incidence of skeletal abnormalities at doses 5-13 times human . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.